Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Carcinoma, Basal Cell / chemically induced
• Carcinoma, Basal Cell / prevention & control*
• Carcinoma, Squamous Cell / chemically induced
• Carcinoma, Squamous Cell / prevention & control*
• Drug Eruptions / etiology
• Drug Eruptions / prevention & control*
• Female
• Humans
• Imidazoles / administration & dosage
• Imidazoles / adverse effects
• Indoles / administration & dosage
• Indoles / adverse effects
• Keratoacanthoma / chemically induced
• Keratoacanthoma / prevention & control
• Keratoderma, Palmoplantar / chemically induced
• Keratoderma, Palmoplantar / prevention & control
• Keratosis, Actinic / chemically induced
• Keratosis, Actinic / prevention & control
• Keratosis, Seborrheic / chemically induced
• Keratosis, Seborrheic / prevention & control
• Male
• Melanoma / drug therapy*
• Middle Aged
• Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
• Oximes / administration & dosage
• Oximes / adverse effects
• Photosensitivity Disorders / chemically induced
• Photosensitivity Disorders / prevention & control
• Proto-Oncogene Proteins B-raf / antagonists & inhibitors
• Pyridones / administration & dosage
• Pyrimidinones / administration & dosage
• Skin Neoplasms / drug therapy*
• Sulfonamides / administration & dosage
• Sulfonamides / adverse effects
• Vemurafenib